ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA approves Amgen's Nplate for certain paediatric patients with immune thrombocytopaenia
December 17, 2018Amgen on Friday announced that the FDA expanded the indication for Nplate (romiplostim) to include its use in paediatric patients aged one year and older with immune thrombocytopaenia (ITP) for at least six months who experienced an insufficient response -
FDA approves Amgen's Nplate for certain paediatric patients with immune thrombocytopaenia
December 17, 2018Amgen on Friday announced that the FDA expanded the indication for Nplate (romiplostim) to include its use in paediatric patients aged one year and older with immune thrombocytopaenia (ITP) for at least six months who experienced an insufficient response
Pharma Sources Insight January 2025
